John Libbey Eurotext

Hématologie

MENU

Practical guide on the use of second-line treatment in multiple myeloma Volume 20, issue 4, Juillet-Août 2014

Figures

  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4
  • Figure 5

Tables

Authors
1 Service d’hématologie,
CHU Nancy-Brabois,
Vandoeuvre lès Nancy
2 Service d’hématologie clinique,
CHU Purpan,
Toulouse
3 Service d’hématologie,
CHU Lyon-Sud,
Lyon
4 Service de cancérologie, hématologie, thérapie cellulaire,
CHRU de Tours,
Tours
5 Service d’immunologie clinique,
CHU Saint-Louis,
Paris
6 Service des maladies du sang,
Hôpital Huriez,
CHRU,
Lille,
France
* Tirés à part

Significant progress has been made in the treatment of Multiple Myeloma and clinicians now have access to a broad variety of therapeutic agents. While first-line treatments are currently well-defined in France, the therapeutic options after first relapse are numerous and non-consensual. In order to propose a clear decision algorithm applicable to most first-relapse situations, a group of French haematology experts was formed. The answers provided are based on an exhaustive analysis of the literature, but also on their day-to-day experience and on the indications of the various molecules for which French marketing authorisations (MAs) have been granted. The purpose of this practical guide on the treatment of first-relapse multiple myeloma is to assist clinicians in their choice of second-line treatment and proposes two treatment algorithms (i) in subjects having undergone intensive first-line treatment and (ii) in subjects having received alkylating agent and corticosteroid (Melphalan-Prednisone) based first-line chemotherapy.